Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Original Article

T. Powles, B.P. Valderrama, S. Gupta, J. Bedke, E. Kikuchi, J. Hoffman-Censits, G. Iyer, C. Vulsteke, S.H. Park, S.J. Shin, D. Castellano, G. Fornarini, J.-R. Li, M. Gümüş, N. Mar, Y. Loriot, A. Fléchon, I. Duran, A. Drakaki, S. Narayanan, X. Yu, S. Gorla, B.H. Moreno, and M.S.v.d. Heijden

N Engl J Med 2024;390:875-888

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
03/06/2024
Course expires: 
03/07/2026

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Please sign in or create an account to take the course.